Ricerca avanzata

Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2014 Giugno;105(3) > Minerva Medica 2014 Giugno;105(3):221-8



Rivista di Medicina Interna

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

Periodicità: Bimestrale

ISSN 0026-4806

Online ISSN 1827-1669


Minerva Medica 2014 Giugno;105(3):221-8


Safety of fondaparinux in the prevention of venous thromboembolism in elderly medical patients: results of a single-center, retrospective study

Silvestri F. 1, Pasca S. 2, Labombarda A. 1, Barbi A. 1, Desideri M. 1, Guidi P. 1, Rogato A. 1, Zaramella M. 1, Bergamo M. 1, Ageno W. 3, Barillari G. 2

1 Division of Internal Medicine, General Hospital, Latisana, Udine, Italy;
2 Center for Hemorrhagic and Thrombotic Diseases, University Hospital, Udine, Italy;
3 Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy

AIM: Venous thromboembolism (VTE) is one of the leading causes of morbidity and mortality in acutely ill medical patients. Fondaparinux is recommended for the prevention of VTE in this setting, but little information is available on its safety and effectiveness in unselected, “real world” patients. The aim of this paper was to assess the safety and efficacy of fondaparinux in elderly acutely ill medical patients.
METHODS: Single center, retrospective study. All patients >60 years, admitted for acute medical disease, bedridden for at least four days and treated with fondaparinux were evaluated. Occurrence of objectively documented, symptomatic VTE, and of bleeding events during the treatment period and follow-up were reported.
RESULTS: Two hundred and ten patients (median age 81 years) were treated with fondaparinux. Seventy patients received fondaparinux 1.5 mg daily, 140 received the 2.5 mg daily dose. However, 29 patients in the first group (with a CrCl≥50 mL/min) and 84 patients in the last group (with a CrCl<50 mL/min) did not receive the correct dose of fondaparinux. During treatment, one episode (0.48%, 95% CI 0.1% to 2.6%) of major bleeding and 6 episodes (2.86%, 95% CI 1.3% to 6.1%) of clinically relevant non major bleeding were recorded. Only one thromboembolic event (0.48%, 95% CI 0.1% to 2.6%) was documented. Thirty-nine patients died; no death was related to VTE, unlike one death was due to major bleeding. Cancer was the only significant predictor of bleeding at statistical analysis.
CONCLUSION: In elderly acutely ill hospitalized medical patients, thromboprophylaxis with fondaparinux 2.5 or 1.5mg daily is safe and effective in preventing VTE without increasing bleeding risk.

lingua: Inglese


inizio pagina